 Sharon Pine
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 32 | 2025 | 2660 | 2.900 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 10 | 2025 | 1186 | 1.470 |
Why?
| | Amyloid Precursor Protein Secretases | 3 | 2018 | 76 | 1.140 |
Why?
| | Biomarkers, Tumor | 12 | 2025 | 1319 | 1.130 |
Why?
| | SOX9 Transcription Factor | 3 | 2023 | 27 | 1.100 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 4 | 2007 | 10 | 0.800 |
Why?
| | Receptor, Notch1 | 2 | 2014 | 63 | 0.790 |
Why?
| | GATA1 Transcription Factor | 4 | 2007 | 18 | 0.760 |
Why?
| | DNA, Neoplasm | 4 | 2010 | 158 | 0.710 |
Why?
| | Janus Kinases | 1 | 2021 | 20 | 0.700 |
Why?
| | STAT Transcription Factors | 1 | 2021 | 24 | 0.700 |
Why?
| | Paclitaxel | 2 | 2022 | 256 | 0.650 |
Why?
| | Signal Transduction | 9 | 2021 | 5185 | 0.620 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2025 | 643 | 0.620 |
Why?
| | Neoplastic Stem Cells | 3 | 2013 | 407 | 0.570 |
Why?
| | Inflammation | 4 | 2022 | 2870 | 0.550 |
Why?
| | Protease Inhibitors | 1 | 2018 | 101 | 0.540 |
Why?
| | Benzodiazepinones | 1 | 2017 | 18 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1437 | 0.520 |
Why?
| | Neoplasms | 4 | 2025 | 2873 | 0.510 |
Why?
| | Cell Line, Tumor | 13 | 2023 | 3523 | 0.500 |
Why?
| | Antineoplastic Agents | 7 | 2023 | 2201 | 0.490 |
Why?
| | Down Syndrome | 4 | 2007 | 522 | 0.490 |
Why?
| | F-Box Proteins | 1 | 2016 | 23 | 0.480 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 176 | 0.480 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2005 | 293 | 0.470 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2016 | 153 | 0.450 |
Why?
| | Polymerase Chain Reaction | 5 | 2010 | 1047 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2021 | 881 | 0.440 |
Why?
| | Interleukin-8 | 3 | 2014 | 269 | 0.440 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 191 | 0.430 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 4 | 0.410 |
Why?
| | Chromosome Segregation | 1 | 2013 | 48 | 0.400 |
Why?
| | DNA Damage | 1 | 2016 | 430 | 0.390 |
Why?
| | DNA | 2 | 2022 | 1447 | 0.360 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 628 | 0.360 |
Why?
| | Interleukin-6 | 3 | 2019 | 770 | 0.360 |
Why?
| | C-Reactive Protein | 2 | 2011 | 420 | 0.350 |
Why?
| | Adenocarcinoma | 3 | 2017 | 923 | 0.340 |
Why?
| | Mannose-Binding Lectin | 2 | 2009 | 20 | 0.340 |
Why?
| | Smoking | 6 | 2024 | 1467 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2012 | 67 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2017 | 211 | 0.320 |
Why?
| | Humans | 52 | 2025 | 144667 | 0.320 |
Why?
| | Case-Control Studies | 14 | 2024 | 3603 | 0.310 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2021 | 337 | 0.310 |
Why?
| | Mutation | 9 | 2023 | 4081 | 0.300 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2019 | 2137 | 0.290 |
Why?
| | Mice | 12 | 2023 | 18261 | 0.280 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 613 | 0.280 |
Why?
| | Cytokines | 1 | 2015 | 2045 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2021 | 503 | 0.260 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 254 | 0.260 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2007 | 14 | 0.260 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 437 | 0.250 |
Why?
| | Lymphoproliferative Disorders | 1 | 2007 | 57 | 0.250 |
Why?
| | Leukemia | 2 | 2007 | 245 | 0.250 |
Why?
| | Animals | 14 | 2023 | 37948 | 0.240 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 124 | 0.230 |
Why?
| | Nuclear Weapons | 1 | 2025 | 7 | 0.230 |
Why?
| | Cell Proliferation | 7 | 2021 | 2489 | 0.230 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2025 | 100 | 0.220 |
Why?
| | Female | 31 | 2025 | 78304 | 0.200 |
Why?
| | Carboplatin | 2 | 2022 | 161 | 0.200 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2365 | 0.200 |
Why?
| | Smokers | 1 | 2024 | 137 | 0.200 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 729 | 0.190 |
Why?
| | Genes, ras | 1 | 2023 | 96 | 0.190 |
Why?
| | Aged | 19 | 2024 | 25955 | 0.190 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 175 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2025 | 247 | 0.180 |
Why?
| | Base Sequence | 4 | 2014 | 2177 | 0.180 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 108 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2014 | 211 | 0.180 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2022 | 454 | 0.180 |
Why?
| | Cell Movement | 3 | 2020 | 959 | 0.180 |
Why?
| | Pyrazines | 1 | 2022 | 92 | 0.170 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 138 | 0.170 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 1 | 2021 | 3 | 0.170 |
Why?
| | Superoxide Dismutase-1 | 1 | 2021 | 10 | 0.170 |
Why?
| | Organelle Biogenesis | 1 | 2021 | 14 | 0.170 |
Why?
| | Immunity, Innate | 1 | 2007 | 843 | 0.170 |
Why?
| | Cytokinesis | 1 | 2021 | 50 | 0.170 |
Why?
| | Triazoles | 1 | 2022 | 184 | 0.170 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 76 | 0.160 |
Why?
| | Middle Aged | 18 | 2024 | 35971 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 380 | 0.160 |
Why?
| | Receptors, Kisspeptin-1 | 1 | 2020 | 2 | 0.160 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2909 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 435 | 0.160 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2019 | 9 | 0.160 |
Why?
| | Prognosis | 7 | 2024 | 4312 | 0.160 |
Why?
| | Male | 25 | 2025 | 72431 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 342 | 0.150 |
Why?
| | Janus Kinase 2 | 1 | 2019 | 29 | 0.150 |
Why?
| | Molecular Chaperones | 1 | 2021 | 181 | 0.150 |
Why?
| | Mice, Inbred NOD | 2 | 2020 | 610 | 0.150 |
Why?
| | Cellular Senescence | 2 | 2013 | 223 | 0.150 |
Why?
| | Cellular Reprogramming | 1 | 2020 | 99 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 452 | 0.140 |
Why?
| | Neoplasm, Residual | 3 | 2005 | 139 | 0.140 |
Why?
| | Biomarkers | 2 | 2021 | 4261 | 0.140 |
Why?
| | Acrylamides | 1 | 2019 | 73 | 0.140 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1268 | 0.140 |
Why?
| | Nanotechnology | 1 | 2019 | 121 | 0.140 |
Why?
| | Aniline Compounds | 1 | 2019 | 121 | 0.140 |
Why?
| | Proteolysis | 2 | 2016 | 170 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 227 | 0.130 |
Why?
| | Risk Factors | 8 | 2015 | 10796 | 0.130 |
Why?
| | Quinolines | 1 | 2019 | 192 | 0.130 |
Why?
| | Receptors, Notch | 1 | 2018 | 90 | 0.130 |
Why?
| | Quinazolines | 1 | 2019 | 266 | 0.130 |
Why?
| | Transcriptome | 1 | 2024 | 1036 | 0.130 |
Why?
| | Transfection | 2 | 2017 | 924 | 0.130 |
Why?
| | Lung | 4 | 2022 | 4089 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2013 | 532 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 650 | 0.130 |
Why?
| | CD24 Antigen | 2 | 2013 | 18 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2020 | 217 | 0.130 |
Why?
| | F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 6 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 330 | 0.120 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 503 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2013 | 104 | 0.120 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 72 | 0.120 |
Why?
| | Ubiquitination | 1 | 2016 | 117 | 0.120 |
Why?
| | Coculture Techniques | 2 | 2013 | 245 | 0.120 |
Why?
| | Proportional Hazards Models | 2 | 2011 | 1322 | 0.120 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 146 | 0.110 |
Why?
| | Cell Division | 3 | 2013 | 753 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 224 | 0.110 |
Why?
| | Receptors, Interleukin-8B | 1 | 2014 | 23 | 0.110 |
Why?
| | Cell Death | 1 | 2016 | 382 | 0.110 |
Why?
| | Protein Isoforms | 2 | 2013 | 396 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 681 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 881 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 971 | 0.100 |
Why?
| | Gene Expression Profiling | 4 | 2025 | 1766 | 0.100 |
Why?
| | Patient Selection | 1 | 2018 | 727 | 0.100 |
Why?
| | 3' Untranslated Regions | 1 | 2014 | 150 | 0.100 |
Why?
| | Software | 1 | 2019 | 695 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2847 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2020 | 927 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 384 | 0.100 |
Why?
| | Platinum Compounds | 1 | 2013 | 11 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 849 | 0.100 |
Why?
| | Genes, T-Cell Receptor | 2 | 2003 | 6 | 0.100 |
Why?
| | Research Design | 2 | 2011 | 1129 | 0.100 |
Why?
| | Dipeptides | 1 | 2013 | 56 | 0.100 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2003 | 30 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2003 | 85 | 0.090 |
Why?
| | Models, Biological | 2 | 2019 | 1811 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2591 | 0.090 |
Why?
| | Alleles | 3 | 2014 | 886 | 0.090 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 152 | 0.090 |
Why?
| | Survival Analysis | 2 | 2013 | 1370 | 0.090 |
Why?
| | Stromal Cells | 1 | 2012 | 120 | 0.090 |
Why?
| | Phosphorylation | 1 | 2016 | 1704 | 0.090 |
Why?
| | Gap Junctions | 1 | 2012 | 67 | 0.090 |
Why?
| | Genotype | 4 | 2014 | 1847 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3148 | 0.090 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2011 | 52 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 321 | 0.080 |
Why?
| | Risk Assessment | 3 | 2011 | 3729 | 0.080 |
Why?
| | Japan | 2 | 2025 | 145 | 0.080 |
Why?
| | Cell Communication | 1 | 2012 | 325 | 0.080 |
Why?
| | Melanoma | 1 | 2017 | 757 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2243 | 0.080 |
Why?
| | ROC Curve | 2 | 2024 | 618 | 0.080 |
Why?
| | AC133 Antigen | 1 | 2010 | 20 | 0.080 |
Why?
| | Adult | 8 | 2020 | 40489 | 0.080 |
Why?
| | Bromodeoxyuridine | 1 | 2010 | 77 | 0.080 |
Why?
| | Phenotype | 3 | 2013 | 3147 | 0.080 |
Why?
| | Biopsy | 2 | 2017 | 1079 | 0.070 |
Why?
| | Logistic Models | 2 | 2011 | 2114 | 0.070 |
Why?
| | Exons | 2 | 2008 | 362 | 0.070 |
Why?
| | Infant | 3 | 2007 | 10023 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2012 | 2350 | 0.070 |
Why?
| | DNA Replication | 1 | 2010 | 252 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 353 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2008 | 2037 | 0.070 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2007 | 26 | 0.070 |
Why?
| | Baltimore | 1 | 2007 | 72 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 915 | 0.060 |
Why?
| | Tobacco Smoke Pollution | 1 | 2009 | 227 | 0.060 |
Why?
| | Smoking Cessation | 1 | 2011 | 436 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 156 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2007 | 249 | 0.060 |
Why?
| | Prospective Studies | 2 | 2011 | 7994 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 552 | 0.060 |
Why?
| | Autophagy | 2 | 2023 | 284 | 0.060 |
Why?
| | DNA Primers | 2 | 2008 | 507 | 0.060 |
Why?
| | Superoxide Dismutase | 1 | 2008 | 303 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2007 | 6399 | 0.060 |
Why?
| | ErbB Receptors | 2 | 2019 | 632 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 323 | 0.060 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1465 | 0.060 |
Why?
| | Haplotypes | 1 | 2007 | 495 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2117 | 0.060 |
Why?
| | Disease-Free Survival | 1 | 2007 | 768 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2021 | 334 | 0.060 |
Why?
| | Preservation, Biological | 1 | 2005 | 7 | 0.060 |
Why?
| | Remission Induction | 1 | 2005 | 309 | 0.050 |
Why?
| | Liquid Biopsy | 1 | 2024 | 14 | 0.050 |
Why?
| | United States | 3 | 2020 | 16018 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2005 | 535 | 0.050 |
Why?
| | MicroRNAs | 3 | 2019 | 689 | 0.050 |
Why?
| | History, 21st Century | 1 | 2025 | 220 | 0.050 |
Why?
| | Tobacco Smoking | 1 | 2024 | 26 | 0.050 |
Why?
| | History, 20th Century | 1 | 2025 | 327 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 3109 | 0.050 |
Why?
| | Peptides | 1 | 2010 | 989 | 0.050 |
Why?
| | Chronology as Topic | 1 | 2003 | 2 | 0.050 |
Why?
| | Chromosome Breakage | 1 | 2003 | 23 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3414 | 0.050 |
Why?
| | Gene Expression | 1 | 2008 | 1476 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 126 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 263 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 75 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2397 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2003 | 318 | 0.040 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2003 | 89 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1246 | 0.040 |
Why?
| | Cell Nucleolus | 1 | 2021 | 19 | 0.040 |
Why?
| | Child | 4 | 2009 | 22600 | 0.040 |
Why?
| | Adenosine | 1 | 2022 | 255 | 0.040 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2021 | 93 | 0.040 |
Why?
| | Down-Regulation | 1 | 2022 | 616 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2021 | 374 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.040 |
Why?
| | Glutaminase | 1 | 2020 | 11 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 7140 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 547 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 454 | 0.040 |
Why?
| | RNA Precursors | 1 | 2021 | 154 | 0.040 |
Why?
| | Africa, Western | 1 | 2019 | 21 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 677 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 75 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2019 | 34 | 0.040 |
Why?
| | Glutamine | 1 | 2020 | 108 | 0.040 |
Why?
| | Recurrence | 1 | 2003 | 1136 | 0.040 |
Why?
| | Exome | 1 | 2020 | 227 | 0.040 |
Why?
| | Nucleotides | 1 | 2020 | 130 | 0.040 |
Why?
| | Mice, SCID | 1 | 2020 | 368 | 0.040 |
Why?
| | Child, Preschool | 2 | 2005 | 11790 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2022 | 470 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 409 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 324 | 0.030 |
Why?
| | Incidence | 2 | 2019 | 2892 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2020 | 167 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 519 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 925 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 205 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2021 | 592 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2019 | 313 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1484 | 0.030 |
Why?
| | Immunotherapy | 1 | 2022 | 662 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2003 | 875 | 0.030 |
Why?
| | Risk | 1 | 2019 | 911 | 0.030 |
Why?
| | Young Adult | 3 | 2020 | 14122 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1726 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 318 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 117 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5414 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 519 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 306 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 504 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 691 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2089 | 0.030 |
Why?
| | Leupeptins | 1 | 2013 | 13 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1092 | 0.030 |
Why?
| | Macrolides | 1 | 2013 | 69 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2013 | 131 | 0.020 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2012 | 19 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 662 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1307 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 441 | 0.020 |
Why?
| | Cohort Studies | 2 | 2012 | 5957 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4539 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1363 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5967 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5870 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 985 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 331 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 472 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 402 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 386 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11735 | 0.020 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 121 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 794 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2008 | 73 | 0.020 |
Why?
| | Adolescent | 2 | 2009 | 22409 | 0.020 |
Why?
| | Homozygote | 1 | 2008 | 200 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 1145 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 845 | 0.020 |
Why?
| | Odds Ratio | 1 | 2010 | 1076 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 303 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 256 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8284 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 973 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4110 | 0.010 |
Why?
| | Erythroid-Specific DNA-Binding Factors | 1 | 2005 | 17 | 0.010 |
Why?
| | Environmental Exposure | 1 | 2009 | 574 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1652 | 0.010 |
Why?
| | Aneuploidy | 1 | 2005 | 90 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1374 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2014 | 17149 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1961 | 0.010 |
Why?
|
|
Pine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|